Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer

BACKGROUND: Currently available third- or later-line therapy for metastatic colorectal cancer (mCRC) is limited in its efficacy, with a weak survival benefit in patients who progressed after two or more lines of standard therapy. Our retrospective study aimed to explore the value of bevacizumab plus...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Yang, Qiong, Yin, Chenxi, Liao, Fangxin, Huang, Yuanyuan, He, Wenzhuo, Jiang, Chang, Guo, Guifang, Zhang, Bei, Xia, Liangping
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562721/
https://ncbi.nlm.nih.gov/pubmed/26366095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S88679
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky